•Contrave will be launched with a larger sales force than both Belviq and Qsymia.
•More robust safety data should lead to a larger amount of doctors prescribing Contrave over other options.
•Middle of the road efficacy should be attractive to doctors.
•Contrave could be the first weight loss drug approved in Europe.
The following is an SEC EDGAR document rendered as filed.
Date of Earliest Transaction (MM/DD/YY)
Title of Security
50,000 Price $ 4.782
Lazarus said, noting just two of the risks associated with Contrave. The risk of suicidal thoughts, noted the FDA, is because the drug contains buproprion, an antidepressant, which would signal physicians to use particular cautions when prescribing. It also contains naltrexone, which has been used to treat drug and alcohol dependence. Other listed possible side effects include raised blood pressure and increased heart rate, as well as less significant issues such as nausea, headache, and dry mouth. Qsymia comes with risks that include depression and confusion, while Belviq has been associated with hypoglycemia, hallucinations, depression, painful erections, and a slow heartbeat.
It’s in a different class from the handful of other available anti-obesity drugs, which include five other options such as Qsymia and Belviq
1. American Medical Association began officially recognizing obesity as a disease
2. Contrave works in a different part of the brain, Lazarus explained. In addition to affecting the hypothalamus, as the others Qsymia and Belviq, do, it works in the mesolimbic pathway, also known as the reward pathway. “That’s important,” he explained, “because a lot of people eat out of a sense of rewarding themselves. This turns down that reward system.” He called approval of the drug “awesome,” and said it “gives us a totally new mechanism of treatment.”
Stewragal & Shenzibegal - both is one guy paid by some street vendor on bashing has zero - YES ZERO knowledge on whats going on here.
Orexigen also is pursuing the medicine as a diabetes treatment, which could raises sales in 2020 to $1.2 billion, Andrews said, based on a 65 percent chance it’s cleared for diabetes use.
The FDA had previously rejected Belviq, Qsymia and Contrave on safety concerns, particularly whether the treatments carried heart risks. Qsymia and Belviq are being studied post-approval to determine their effect on the heart.
Orexigen presented an interim analysis of a cardiovascular study the FDA asked for in 2011 to show the drug didn’t present excess risk. That study is expected to be complete in 2016 or 2017 and “could provide a marketing advantage with prescribers from a safety perspective compared to Qsymia and Belviq,” Andrews said.
None of the three weight-loss pills is on the market in Europe. Orexigen’s drug is currently positioned to become the first for sale there in 2015
How can you sell something which you don't have and expect people won't ask you to buy back ?
Thinking if nobody buys you can get cheaper? we kept buying you cheap and so cheap ...finally will have to.Run for the life.
A bullish investor could look at OREX's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side
You oversell something which you don't have and that's short selling bro.....EVERYTHING SELL for the Price ....and that's the game.
This according to Adam -...........................BE CAREFUL
Monday after demonstrating once again that cough syrup produces a nice, mellow high. Alzheimer's patients became less agitated after taking the company's AVP-923 compared to a placebo, according to results from a phase II study.
AVP-923 combines an over-the-counter cough suppressant dextromethorphan with generic quinidine (commonly used to control heartbeats.) Avanir already markets AVP-923 under the brand name Neudexta as a treatment to dull episodes of uncontrolled laughing and crying in patients with pseudobulbar affect. Insurance companies have placed significant restrictions on Neudexta reimbursements, which hampers Avanir's commercial efforts. Neudexta sales only reached $75 million last year and are on track to top $100 million this year. With today's surging stock price, Avanir's market cap approaches $2 billion.
The company believes it can do better by expanding use of AVP-923/Neudexta to treat people who become agitated due to Alzheimer's. But if payers balk at paying for what amounts to over-priced cough syrup to treat the relatively small number of PBA patients, why would they consent to reimbursement for potentially millions of Alzheimer's patients? True drug development innovation this is not.